Table 3

Univariate Cox regression analysis of bridging therapy use and overall survival

VariableHR (95% CI)SEP value
Age1.01 (0.99 to 1.03)0.010.484
Female sex0.68 (0.43 to 1.08)0.160.104
Married/with a life partner0.77 (0.49 to 1.23)0.180.279
Charlson Comorbidity Index score1.00 (0.71 to 1.39)0.170.973
Double hit lymphoma diagnosis1.54 (0.93 to 2.56)0.400.092
Number of prior therapies1.02 (0.89 to 1.17)0.070.762
Prior autologous stem cell transplant0.62 (0.35 to 1.08)0.180.093
Months from relapse to CAR T-cell infusion0.75 (0.57 to 0.99)0.110.041
Vein-to-vein time (months)0.74 (0.33 to 1.66)0.300.462
ECOG performance status1.47 (1.16 to 1.87)0.180.002
LDH >500 (U/L, prior to CAR T-cell infusion)2.06 (1.24 to 3.42)0.530.005
CRP >30 (mg/L, prior to CAR T-cell infusion)2.11 (1.36 to 3.27)0.470.001
Ferritin ≥411 (µg/L, prior to CAR T-cell infusion)1.65 (0.98 to 2.78)0.440.058
Platelet count <100 K/µL1.41 (0.86 to 2.30)0.350.171
Bridging therapy use1.86 (1.20 to 2.89)0.420.005
CD28 co-stimulatory domain CAR T-cell product0.65 (0.37 to 1.17)0.190.152
Dexamethasone dose (dg) from days 0–311.17 (1.07 to 1.28)0.05<0.001
Receipt of tocilizumab0.89 (0.57 to 1.37)0.200.584
  • CAR, chimeric antigen receptor; CRP, C-reactive protein; dg, decigram; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.